|
|
Listing of Epigenomics to occur monday july 19, 2004
 |
 |
| Date: Friday, 16.07.2004 |
|
| Press Release, Berlin |
|
EPIGENOMICS PRICES IPO ON FRANKFURT STOCK EXCHANGE AT €9.00 PER SHARE
Berlin, Germany, July 16, 2004 - Epigenomics AG, a molecular diagnostics company developing tests based on DNA methylation, announced today that shares from its initial public offering on the Frankfurt Stock Exchange have been priced at €9.00 per share. Epigenomics’ shares were admitted to trading on the Official Market (Amtlicher Markt) - Prime Standard of the Frankfurt Stock Exchange on July 14, 2004. The subscription period for the offering ran from July 5 to 16, 2004.
The gross proceeds to Epigenomics from the offering were approximately €41.6 millionen. The gross proceeds may increase to approximately €47.8 million if the over-allotment option is fully exercised and the shares are issued from the authorized capital of the Company.
The Company’s shares were admitted to trading on the official market (Prime Standard segment) of the Frankfurt Stock Exchange on July 14, 2004 and trading will commence on July 19, 2004 under the ticker symbol ECX.
\"The demand from high quality institutional investors reaffirms the strength of our story for our employees and strategic partners as well as providing us with a solid base for future growth," commented Alex Olek, CEO of Epigenomics. "The proceeds raised will allow us to expand our product pipeline by applying our DNA methylation technology to further cancer indications and additional diseases.\"
Details of the Offering
| First day of trading |
![\"\"](\"http://www.epigenomics.com/stepone/data/images/86/00/00/10px.gif\") |
July 19, 2004 (Frankfurt Stock Exchange, Official Market, Prime Standard) |
|
|
|
| Issue price |
|
€ 9,00 per share |
|
|
|
| Gross Proceeds |
|
Approximately €41.6 million (approximately €47.8 if the over-allotment option for 693,277 new shares is fully excised and the shares are issued from the authorized capital of the Company) |
|
|
|
| Settlement |
|
July 21, 2004 |
|
|
|
| Ticker symbol |
|
ECX |
|
|
|
| ISIN |
|
DE000A0BVT96 (für die neuen Aktien) |
|
|
|
| Securities identification code (WKN) |
|
A0BVT9 (for new shares) |
|
|
|
Shares outstanding
(after the offering) |
|
15,974,752 shares (excluding the over-allotment option).
The free float represents approximately 29% (approximately 32% if the over-allotment option is exercised in full and covered from the authorized capital of the Company). |
The consortium consists of Morgan Stanley Bank AG as the sole global coordinator and sole bookrunner, Lehman Brothers International (Europe) as Joint Lead Manager and DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, as Co-Lead Manager.
The company will use the net proceeds of the offering mainly to support a broadening of its diagnostic and pharmacodiagnostic product pipeline as well as the expansion of its research and development activities.
Multiple Products in Development
Epigenomics is developing screening, monitoring, classification and drug response (pharmacodiagnostic) tests, with an initial focus on cancer. The Company has a broad product pipeline in various stages of development. In collaboration with Roche Diagnostics, a world leader in molecular diagnostics, Epigenomics is developing tests to diagnose prostate, colon and breast cancer; a test for staging prostate cancer; and a pharmacodiagnostic test to predict the probability of relapse in women treated with the standard breast cancer treatment, tamoxifen.
DNA Methylation
DNA Methylation is a natural epigenetic process that occurs when a methyl group binds to one of DNA’s four bases, cytosine. The presence of methylation is responsible for controlling the activity of genes by turning them off, like a switch, when not needed. By measuring the differences in the methylation patterns between healthy and diseased tissue, a change in gene activity that could trigger diseases such as cancer is detected. Epigenomics has developed an industrial process that is able to read and interpret these methylation patterns.
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics’ tests can potentially diagnose disease at an early stage and help guide physicians to select the appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic and pharmacodiagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at http://www.epigenomics.com.
Disclaimer
The shares have not been registered under the U.S. Securities Act of 1933, as amended (the \"Securities Act\") and may not be sold in the United States absent registration or an exemption from registration under the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer and that will contain detailed information about the company and management as well as financial statements.
This publication is not an offer for sale or a solicitation to purchase or subscribe for securities. The offer will be made exclusively by means of a prospectus. The German language sales prospectus (Verkaufsprospekt) dated July 2, 2004, the first supplement (Nachtrag) thereto dated July 15th, 2004 and the stock exchange admission prospectus (Börsenzulassungsprospekt) dated July 14, 2004 may be obtained from Morgan Stanley Bank AG, Junghofstr. 13-15, 60311 Frankfurt am Main, from DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, Platz der Republik, 60265 Frankfurt am Main, from Lehman Brothers International (Europe), from Deutsche Börse AG, Abteilung Listing, Neue Börsenstrasse 1, 60487 Frankfurt am Main, and from Epigenomics AG, Kleine Präsidentenstrasse 1, 10178 Berlin. German residents may also download these documents from the web site of the company under http://www.epigenomics.com.
Publications with respect to possible stabilization measures and possible stabilisation consequences pursuant to Section 9(1) of the Regulation for the Implementation of the Prohibition on Market and Price Manipulation (Verordnung zur Konkretisierung des Verbotes der Kurs- und Marktpreismanipulation, "KuMaKV") have been made in the German language sales prospectus (Verkaufsprospekt) dated July 2, 2004, in the stock exchange admission prospectus (Börsenzulassungsprospekt) dated July 14, 2004, in a press release and through a publication on the internet at the address http://www.epigenomics.com. Stabilisation manager is Morgan Stanley Bank AG.
|
|
| back |
|
top of the page
|
